 EDP1815 Phase 2b data in psoriasis expected in 3Q 2021Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021Strengthened leadership team with appointment of Mark Plinio as Chief Commercial OfficerMultiple clinical data readouts expected over next 6-12 monthsManagement to host conference call at 8:30 a.m. ET 